Treatment of depression secondary to pain (dsp)
CA 2493490 A1 · Owner: Cypress Bioscience, Inc. · Inventors: Rao, Srinivas G.; Kranzler, Jay D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods for the prevention or treatment of atypical depression secondary to pain (DSP) have been developed. The method generally involves administering an effective amount of a monoamine re uptake inhibitor to treat or prevent symptoms of DSP. In a preferred embodiment a therapeutically effective amount , of a dual serotonin norepinephrine reuptake inhibitor (SRNI) compound of a specific type, or a pharmaceutically acceptable sait thereof is administered. The most preferred SNRI compounds are non-tricyclic SNRIs wherein serotonin , reuptake inhibition is greater than norepinephrine reuptake inhibition; and NSRIs, wherein norepinephrine reuptake inhibition is greater than serotonin …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 24, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 24, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 24, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.